Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 698542, 8 pages
http://dx.doi.org/10.1155/2014/698542
Review Article

An Overview of Fotemustine in High-Grade Gliomas: From Single Agent to Association with Bevacizumab

1Medical Oncology 1 Unit, Venetian Oncology Institute-IRCCS, Via Gattamelata 64, 35128 Padua, Italy
2Neurosurgery Department, Padua Hospital, Padua, Italy
3Nuclear Medicine Service, Department of Diagnostic Medical Sciences, University of Padua, Padua, Italy

Received 12 February 2014; Accepted 3 March 2014; Published 31 March 2014

Academic Editor: Emeline Tabouret

Copyright © 2014 Giuseppe Lombardi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Y. Wen and S. Kesari, “Malignant gliomas in adults,” The New England Journal of Medicine, vol. 359, pp. 492–507, 2008. View at Publisher · View at Google Scholar
  2. P. Beauchesne, “Fotemustine: a third-generation nitrosourea for the treatment of recurrent malignant gliomas,” Cancers, vol. 4, no. 1, pp. 77–87, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. A. de Rossi, L. Rossi, A. Laudisi et al., “Focus on fotemustine,” Journal of Experimental and Clinical Cancer Research, vol. 25, no. 4, pp. 461–468, 2006. View at Google Scholar · View at Scopus
  4. B. Tranchand, C. Lucas, P. Biron et al., “Phase I pharmacokinetics study of high-dose fotemustine and its metabolite 2-chloroethanol in patients with high-grade gliomas,” Cancer Chemotherapy and Pharmacology, vol. 32, no. 1, pp. 46–52, 1993. View at Google Scholar · View at Scopus
  5. A. Laquerriere, G. Raguenez-Viotte, M. Paraire et al., “Nitrosoureas lomustine, carmustine and fotemustine induced hepatotoxic perturbations in rats: biochemical, morphological and flow cytometry studies,” European Journal of Cancer, vol. 27, no. 5, pp. 630–638, 1991. View at Publisher · View at Google Scholar · View at Scopus
  6. M. J. van den Bent, A. A. Brandes, M. J. Taphoorn et al., “Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951,” Journal of Clinical Oncology, vol. 31, pp. 344–350, 2013. View at Publisher · View at Google Scholar
  7. R. Stupp, W. P. Mason, M. J. van den Bent et al., “Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma,” The New England Journal of Medicine, vol. 352, no. 10, pp. 987–996, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Frenay, B. Giroux, S. Khoury, J. M. Derlon, and M. Namer, “Phase II study of fotemustine in recurrent supratentorial malignant gliomas,” European Journal of Cancer, vol. 27, no. 7, pp. 852–856, 1991. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Ozkan, M. Altinbas, O. Er et al., “Post-operative sequential chemo-radiotherapy in high-grade cerebral gliomas with fotemustine,” Journal of Chemotherapy, vol. 16, no. 3, pp. 298–302, 2004. View at Google Scholar · View at Scopus
  10. B. Fazeny-Dörner, M. Veitl, C. Wenzel et al., “Second-line chemotherapy with dacarbazine and fotemustine in nitrosourea-pretreated patients with recurrent glioblastoma multiforme,” Anti-Cancer Drugs, vol. 14, no. 6, pp. 437–442, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Boiardi, A. Silvani, E. Ciusani et al., “Fotemustine combined with procarbazine in recurrent malignant gliomas: a phase I study with evaluation of lymphocyte O6-alkylguanine-DNA alkyltransferase activity,” Journal of Neuro-Oncology, vol. 52, no. 2, pp. 149–156, 2001. View at Publisher · View at Google Scholar · View at Scopus
  12. M. Frenay, C. Lebrun, M. Lonjon, P. Y. Bondiau, and M. Chatel, “Up-front chemotherapy with fotemustine (F)/cisplatin (CDDP)/etoposide (VP16) regimen in the treatment of 33 non-removable glioblastomas,” European Journal of Cancer, vol. 36, no. 8, pp. 1026–1031, 2000. View at Publisher · View at Google Scholar · View at Scopus
  13. G. Lombardi, F. Zustovich, P. Farina et al., “Hypertension as a biomarker in patients with recurrent glioblastoma treated with antiangiogenic drugs: a single-center experience and a critical review of the literature,” Anticancer Drugs, vol. 24, no. 1, pp. 90–97, 2013. View at Publisher · View at Google Scholar
  14. D. A. Reardon, A. Desjardins, K. B. Peters et al., “Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy,” Cancer, vol. 117, no. 23, pp. 5351–5358, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. F. Zustovich, G. Lombardi, D. Pastorelli et al., “Bevacizumab and glioblastomas, a single-centre experience: how disease history and characteristics may affect clinical outcome,” Anticancer Research, vol. 30, no. 12, pp. 5213–5216, 2010. View at Google Scholar · View at Scopus
  16. H. S. Friedman, M. D. Prados, P. Y. Wen et al., “Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma,” Journal of Clinical Oncology, vol. 27, no. 28, pp. 4733–4740, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. S. Scoccianti, B. Detti, A. Sardaro et al., “Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience,” Anti-Cancer Drugs, vol. 19, no. 6, pp. 613–620, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. A. A. Brandes, A. Tosoni, E. Franceschi et al., “Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO),” Cancer Chemotherapy and Pharmacology, vol. 64, no. 4, pp. 769–775, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. M. G. Fabrini, G. Silvano, I. Lolli et al., “A multi-institutional phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma,” Journal of Neuro-Oncology, vol. 92, no. 1, pp. 79–86, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. R. Addeo, M. Caraglia, M. S. de Santi et al., “A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma,” Journal of Neuro-Oncology, vol. 102, no. 3, pp. 417–424, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Fabi, G. Metro, A. Vidiri et al., “Low-dose fotemustine for recurrent malignant glioma: a multicenter phase II study,” Journal of Neuro-Oncology, vol. 100, no. 2, pp. 209–215, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Santoni, S. Scoccianti, I. Lolli et al., “Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastoma,” Journal of Neuro-Oncology, vol. 113, no. 3, pp. 397–401, 2013. View at Publisher · View at Google Scholar
  23. A. Silvani, E. Lamperti, P. Gaviani et al., “Salvage chemotherapy with procarbazine and fotemustine combination in the treatment of temozolomide treated recurrent glioblastoma patients,” Journal of Neuro-Oncology, vol. 87, no. 2, pp. 143–151, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Santoni, A. Paccapelo, L. Burattini, A. Onofri, and S. Cascinu, “Twice-daily dosing of temozolomide in combination with fotemustine for the treatment of patients with refractory glioblastoma,” Anticancer Research, vol. 32, no. 3, pp. 1099–1101, 2012. View at Google Scholar · View at Scopus
  25. P. Gaviani, A. Salmaggi, and A. Silvani, “Combined chemotherapy with temozolomide and fotemustine in recurrent glioblastoma patients,” Journal of Neuro-Oncology, vol. 104, no. 1, pp. 617–618, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. J. J. Vredenburgh, A. Desjardins, J. E. Herndon II et al., “Bevacizumab plus irinotecan in recurrent glioblastoma multiforme,” Journal of Clinical Oncology, vol. 25, no. 30, pp. 4722–4729, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. D. A. Reardon, J. E. Herndon II, K. Peters et al., “Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients,” Journal of Neuro-Oncology, vol. 107, no. 1, pp. 213–221, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. R. Soffietti, E. Trevisan, L. Bertero et al., “Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology),” Journal of Neuro-Oncology, vol. 116, no. 3, pp. 533–541, 2014. View at Publisher · View at Google Scholar
  29. R. Soffietti, E. Trevisan, C. Bosa, L. Bertero, and R. Rudà, “Phase II trial of bevacizumab and fotemustine in recurrent grade III gliomas,” Journal of Clinical Oncology, vol. 30, 2012, Abstract 2075. View at Google Scholar
  30. W. Taal, H. Oosterkamp, A. Walenkamp et al., “A randomized phase II study of bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma: The Dutch BELOB study,” Journal of Clinical Oncology, vol. 31, 2013, Abstract 2001. View at Google Scholar
  31. A. Meulemans, B. Giroux, P. Hannoun, D. Robine, and D. Henzel, “Comparative diffusion study of two nitrosoureas: carmustine and fotemustine in normal rat brain, human and rat brain biopsies,” Chemotherapy, vol. 37, no. 2, pp. 86–92, 1991. View at Google Scholar · View at Scopus
  32. T. T. Batchelor, P. Mulholland, B. Neyns et al., “Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma,” Journal of Clinical Oncology, vol. 31, pp. 3212–3218, 2013. View at Publisher · View at Google Scholar